Adam Feuerstein

TheStreet.com Senior Columnist

Before joining TheStreet.com in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

Feuerstein graduated from Emory University with a bachelor's degree in political science.

Adam Feuerstein
By This Author:
« Back
Page 1 of 412
Article

Biogen Idec Offers 2010 Guidance: BioBuzz

By Adam Feuerstein

Company forecasts 2010 earnings that exceed Street expectations.

07:50AM 02/09/10

Article

FDA Tough on Cell Therapeutics' Cancer Drug

By Adam Feuerstein

Investors were warned last week about problems with Cell Therapeutics' cancer drug pixantrone.

12:29PM 02/08/10

Article

FDA Raises Concerns About Cell Therapeutics' Cancer Drug

By Adam Feuerstein

Ahead of a Feb. 10 advisory panel meeting, regulators say pivotal trial of pixantrone was too small; they also express concern about heart safety of drug.

09:46AM 02/08/10

Article

AMAG Defends Feraheme Safety: BioBuzz

By Adam Feuerstein

AMAG Pharmaceuticals used a Friday evening conference call to swat down safety concerns about its intravenous iron replacement therapy Feraheme.

07:04AM 02/08/10

Article

Biotech Stock Mailbag: Soligenix

By Adam Feuerstein

Our biotech columnist answers readers' burning questions about Soligenix, Cell Therapeutics, and other biotech stocks.

07:00AM 02/05/10

Article

AMAG Pharma Tumbles on Feraheme Safety Concerns: BioBuzz

By Adam Feuerstein

Analyst downgrade AMAG citing Feraheme patients experiencing severe allergic reactions.

12:15PM 02/04/10

Article

Alkermes Testing its Version of Popular Schizophrenia Drug

By Adam Feuerstein

Ahead of its Q4 earnings report due after the bell, Alkermes announced that it is starting testing of aripiprazole, a top-selling schizophrenia treatment.

08:31AM 02/04/10

Article

10 Biotech Stocks on Clinical Trials Watch

By Adam Feuerstein

News of clinical trial results can make or break a drug. Here are ten companies expected to announce important results in coming months.

06:00AM 02/04/10

Article

Medivation's Alzheimer Trial Data in Early March: Biobuzz

By Adam Feuerstein

Phase III study of Dimebon could be make or break for Medivation's stock price.

10:42AM 02/02/10

Article

Biotech Calendar: Key Dates for February

By Adam Feuerstein

February's list of important, potentially stock-moving biotech events.

06:00AM 02/02/10

« Back
Page 1 of 412
Dow Jones S&P 500 NASDAQ 10-Year Note
10,093.10 1,073.01 2,155.83 36.29
Oil *
72.05
UP
184.71
UP
16.27
UP
29.78
UP
0.37
10 Yr
3.63%
SPDR Gold
105.43
+1.86%
+1.54%
+1.40%
+1.03%
Data delayed 20 minutes

More From TheStreet

Latest Headlines
  • Top Rated Stocks from TheStreet Ratings
  • Find returns with the Dividend Calendar

Brokerage Partners